Last update 25 Feb 2026

Autologous bone marrow derived MSCs therapy(Zimmer Biomet)

Overview

Basic Info

Drug Type
Cell therapy
Synonyms-
Target-
Action-
Mechanism
Cell replacements
Therapeutic Areas
Cardiovascular DiseasesOther Diseases
Active Indication-
Inactive Indication
Chronic Limb-Threatening IschemiaComplicationPerioperative ischaemia
Originator Organization
Zimmer Biomet Holdings, Inc.Zimmer Biomet Holdings, Inc.
Active Organization-
Inactive Organization
Zimmer Biomet Holdings, Inc.Zimmer Biomet Holdings, Inc.
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Autologous bone marrow derived MSCs therapy(Zimmer Biomet)
NCT02863926
/ CompletedPhase 1IIT
Safety and Efficacy of Concentrated Autologous Concentrated Bone Marrow Aspirate (cBMA) in Preventing Wound Complications in Below Knee Amputation (BKA) (The MarrowCHAMP Study)
100 Clinical Results associated with Autologous bone marrow derived MSCs therapy(Zimmer Biomet)
Login to view more data
100 Translational Medicine associated with Autologous bone marrow derived MSCs therapy(Zimmer Biomet)
Login to view more data
100 Patents (Medical) associated with Autologous bone marrow derived MSCs therapy(Zimmer Biomet)
Login to view more data
100 Deals associated with Autologous bone marrow derived MSCs therapy(Zimmer Biomet)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Perioperative ischaemiaPhase 1
United States
Zimmer Biomet Holdings, Inc.Zimmer Biomet Holdings, Inc.
31 Jan 2017
Chronic Limb-Threatening IschemiaPhase 1
United States
Zimmer Biomet Holdings, Inc.Zimmer Biomet Holdings, Inc.
06 Jan 2017
ComplicationPhase 1
United States
Zimmer Biomet Holdings, Inc.Zimmer Biomet Holdings, Inc.
06 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02863926 (MarrowCHAMP, CTgov)
Phase 1
Chronic Limb-Threatening Ischemia | Complication
6
(Day 7)
mdhsqseixb = puqrrtyrwy cugvwnjyjd (cxfdyftkyp, jpjhylcnxm - pgrhbqcgac)
View more
-
12 Dec 2024
(Day 21)
mdhsqseixb = krbqmkrfqf cugvwnjyjd (cxfdyftkyp, ivlswxxlpt - lraeccakpv)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free